Tolerability of ragweed allergy immunotherapy in patients with allergic rhinoconjunctivitis.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 27 Feb 2013 New trial record
- 22 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.